Cholesterol and atherosclerosis: Modulation by oestrogen

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 214-220

  Barton, Matthias ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Coronary artery disease; Menopause; Myocardial infarction; Oestrogen; Ovarian function

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HIGH DENSITY LIPOPROTEIN; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HEART INFARCTION; HORSE; HUMAN; INFLAMMATION; LIPID METABOLISM; MENOPAUSE; OVARY FUNCTION; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; URINE;

ADULT; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CORONARY ARTERY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPID METABOLISM; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EQUIDAE;

EID: 84880134748     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283613a94     Document Type: Review

References (69)

1. Abdelfattah A, Allam AH, Wann S, et al. Atherosclerotic cardiovascular disease in Egyptian women: 1570 BCE-2011 CE. Int J Cardiol (in press).
2. Heberden W. Commentaries on the history and cure of diseases. London: Mews-Gate; 1802.
3. Barton M. Sex and NO-beyond regulation of vasomotor tone. Cardiovasc Res 2000; 46:20-23. (Pubitemid 30155941)
4. Bittner V. Menopause and cardiovascular risk cause or consequence? J Am Coll Cardiol 2006; 47:1984-1986.
5. Barrett-Connor E. Menopause, atherosclerosis, and coronary artery disease. Curr Opin Pharmacol (in press).
6. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981; 141:1128-1131. (Pubitemid 11017493)
7. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholester-olemia. Implications for pathogenesis and therapy. Med Clin North Am 1982; 66:335-362. (Pubitemid 12115370)
8. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010; 21:289-297.
9. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab 2012; 97:3399-3407.
10. Babelova A, Sedding DG, Brandes RP. Antiatherosclerotic mechanisms of statin therapy. Curr Opin Pharmacol (in press).
11. Shuto H, Tominaga K, Yamauchi A, et al. The statins fluvastatin and pravas-tatin exert antiflushing effects by improving vasomotor dysfunction through nitric oxide-mediated mechanisms in ovariectomized animals. Eur J Pharmacol 2011; 651:234-239.
12. Qin C, Singh P, Safe S. Transcriptional activation of insulin-like growth factorbinding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 1999; 140:2501-2508. (Pubitemid 32245126)
13. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003; 2:332-338. (Pubitemid 37211387)
14. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 2006; 47:1019-1026. (Pubitemid 44289154)
15. Meyer MR, Haas E, Prossnitz ER, Barton M. Nongenomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol 2009; 308:9-16.
16. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev 2008; 60:210-241. (Pubitemid 351962010)
17. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary artery disease and lipid levels. Lancet 1959; 2:600-604.
18. Knopp RH, Paramsothy P, Retzlaff BM, et al. Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep 2006; 8:452-459. (Pubitemid 44742140)
19. Schmermund A, Erbel R, Silber S. Age and gender distribution of coronary artery calcium measured by four-slice computed tomography in 2030 persons with no symptoms of coronary artery disease. Am J Cardiol 2002; 90:168-173. (Pubitemid 34775130)
20. Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16:917-928. (Pubitemid 41710302)
21. Emmanuele L, Ortmann J, Doerflinger T, et al. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 2003; 302:67-72. (Pubitemid 36268920)
22. Choi BG, Vilahur G, Zafar MU, et al. Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 2008; 201:76-84.
23. McGill HC Jr, Herderick EE, McMahan CA, et al. Atherosclerosis in youth. Minerva Pediatr 2002; 54:437-447.
24. McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712-2718. (Pubitemid 34615140)
25. Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? Arterioscler Thromb Vasc Biol 2007; 27:1669-1672. (Pubitemid 47207158)
26. Barton M. Childhood obesity: a life-long health risk. Acta Pharmacol Sin 2012; 33:189-193.
27. Kok HS, van Asselt KM, van der Schouw YT, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006; 47:1976-1983.
28. Anichkov NN, Chalatov S. Uber die experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat 1913; 24:1-9.
29. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002; 15:439-446. (Pubitemid 35387383)
30. Yla-Herttuala S, Bentzon JF, Daemen M, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2001; 106:1-19.
31. Virchow R. Der atheromatöse Prozess der Arterien. Wien Med Wochenschr 1856; 6:809-812.
32. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 2001; 141:S58-S62. (Pubitemid 32128720)
33. Kolodgie FD, Jacob A, Wilson PS, et al. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996; 148:969-976. (Pubitemid 126660688)
34. Palinski W, Napoli C. Pathophysiological events during pregnancy influence the development of atherosclerosis in humans. Trends Cardiovasc Med 1999; 9:205-214.
35. Meyer MR, Barton M. ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovasc Res 2009; 83:605-610.
36. Hodgin JB, Krege JH, Reddick RL, et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in ApoE-/-mice. J Clin Invest 2001; 107:333-340. (Pubitemid 32157965)
37. Villablanca AC, Tenwolde A, Lee M, et al. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res 2009; 2:289-299.
38. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613. (Pubitemid 28502636)
39. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7:715-726.
40. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci U S A 2002; 99:4055-4060. (Pubitemid 34252228)
41. Meyer MR, Haas E, Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend Med 2008; 2008:S19-S33. (Pubitemid 351455229)
42. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987; 210:37-39. (Pubitemid 17233457)
43. Gardner G, Banka CL, Roberts KA, et al. Modified LDL-mediated increases in endothelial layer permeability are attenuated with 17beta-estradiol. Arterios-cler Thromb Vasc Biol 1999; 19:854-861. (Pubitemid 29177329)
44. Walsh BA, Mullick AE, Walzem RL, Rutledge JC. 17beta-estradiol reduces tumor necrosis factor-alpha-mediated LDL accumulation in the artery wall. J Lipid Res 1999; 40:387-396. (Pubitemid 29116141)
45. Colvin PL Jr. Estrogen increases low-density lipoprotein receptor-independent catabolism of apolipoprotein B in hyperlipidemic rabbits. Metabolism 1996; 45:889-896. (Pubitemid 26249758)
46. Wolfe BM, Huff MW. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women. J Clin Invest 1989; 83:40-45. (Pubitemid 19048402)
47. Sulistiyani, St Clair RW. Effect of 17 beta-estradiol on metabolism of acety-lated low density lipoprotein by THP-1 macrophages in culture. Arterioscler Thromb Vasc Biol 1997; 17:1691-1700.
48. Nofer JR. Estrogens and atherosclerosis: insights from animal models and cell systems. J Mol Endocrinol 2012; 48:R13-R29.
49. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994; 35:2083-2093. (Pubitemid 24353080)
50. Srivastava RA. Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice. A possible mechanism of atheroprotection by estrogen. Mol Cell Biochem 2002; 240:67-73. (Pubitemid 35385821)
51. Herrington DM. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol 2003; 14:145-150. (Pubitemid 36521184)
52. Stangl H, Graf GA, Yu L, et al. Effect of estrogen on scavenger receptor BI expression in the rat. J Endocrinol 2002; 175:663-672. (Pubitemid 36054238)
53. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346:967-974. (Pubitemid 34983246)
54. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121:2693-2708.
55. Miller AP, Xing D, Feng W, et al. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007; 14:251-260. (Pubitemid 46673477)
56. Low AK, Russell LD, Holman HE, et al. Hormone replacement therapy and coronary heart disease in women: a review of the evidence. Am J Med Sci 2002; 324:180-184.
57. Barton M. Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection? Expert Opin Investig Drugs 2001; 10:789-809. (Pubitemid 32427653)
58. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8:3-12. (Pubitemid 40675116)
59. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522-529. (Pubitemid 30650747)
60. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349:535-545. (Pubitemid 36951365)
61. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591-2602. (Pubitemid 46961004)
62. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409.
63. Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010; 122:1716-1724.
64. Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012; 110:3A-14A.
65. Gotto AM Jr, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol 2012; 110:15A-26A.
66. Schiffrin EL, Scheppard R. Inhibition of the renin-angiotensin system for lowering coronary artery disease risk. Curr Opin Pharmacol (in press).
67. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013; 62 (Suppl 1):S15-S19.
68. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005;352:1138-1145. (Pubitemid 40365358)
69. Mosca L, Hammond G, Mochari-Greenberger H, et al., on behalf of the American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on High Blood Pressure Research, and Council on Nutrition, Physical Activity and Metabolism. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association National Survey. Circulation 2013; 127:1254-1263.